Guangdong Zhongsheng Pharmaceutical Co., Ltd.

SZSE:002317 주식 보고서

시가총액: CN¥11.0b

Guangdong Zhongsheng Pharmaceutical 미래 성장

Future 기준 확인 4/6

Guangdong Zhongsheng Pharmaceutical (는) 각각 연간 41.7% 및 16.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 41.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.7% 로 예상됩니다.

주요 정보

41.7%

수익 성장률

41.2%

EPS 성장률

Pharmaceuticals 수익 성장18.8%
매출 성장률16.3%
향후 자기자본 수익률8.7%
애널리스트 커버리지

Low

마지막 업데이트21 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Nov 04
We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Investor Optimism Abounds Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) But Growth Is Lacking

Oct 07
Investor Optimism Abounds Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) But Growth Is Lacking

These 4 Measures Indicate That Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Is Using Debt Reasonably Well

Jul 12
These 4 Measures Indicate That Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Is Using Debt Reasonably Well

Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) P/E Is On The Mark

Jun 18
Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) P/E Is On The Mark

Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Has Affirmed Its Dividend Of CN¥0.20

May 20
Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Has Affirmed Its Dividend Of CN¥0.20

We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Apr 29
We Think You Can Look Beyond Guangdong Zhongsheng Pharmaceutical's (SZSE:002317) Lackluster Earnings

Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Mar 18
Does Guangdong Zhongsheng Pharmaceutical (SZSE:002317) Have A Healthy Balance Sheet?

Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Shares Climb 29% But Its Business Is Yet to Catch Up

Feb 29
Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) Shares Climb 29% But Its Business Is Yet to Catch Up

수익 및 매출 성장 예측

SZSE:002317 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20263,608431N/A3201
12/31/20253,121362N/A2921
12/31/20242,732244N/A1581
9/30/20242,447133219435N/A
6/30/20242,49314298340N/A
3/31/20242,505175-36257N/A
12/31/20232,611263-172191N/A
9/30/20232,756353-446-21N/A
6/30/20232,833328-447-37N/A
3/31/20232,747387-466-108N/A
1/1/20232,676322-20563N/A
9/30/20222,597213241441N/A
6/30/20222,545192411617N/A
3/31/20222,489295400598N/A
1/1/20222,429278409623N/A
9/30/20212,409-414-97100N/A
6/30/20212,321-330-15013N/A
3/31/20212,122-423-27126N/A
12/31/20201,896-427-16139N/A
9/30/20201,923251181323N/A
6/30/20202,010207189336N/A
3/31/20202,30724495240N/A
12/31/20192,532318123251N/A
9/30/20192,538454220356N/A
6/30/20192,474464320455N/A
3/31/20192,378439325449N/A
12/31/20182,362436183327N/A
9/30/20182,306455229381N/A
6/30/20182,197447N/A274N/A
3/31/20182,125432N/A192N/A
12/31/20171,964420N/A370N/A
9/30/20171,855427N/A223N/A
6/30/20171,837439N/A230N/A
3/31/20171,713432N/A297N/A
12/31/20161,692414N/A338N/A
9/30/20161,673380N/A274N/A
6/30/20161,640371N/A351N/A
3/31/20161,668325N/A334N/A
12/31/20151,578297N/A192N/A
9/30/20151,494276N/A356N/A
6/30/20151,433257N/A219N/A
3/31/20151,367238N/A75N/A
12/31/20141,309225N/A101N/A
9/30/20141,234219N/A96N/A
6/30/20141,190211N/A97N/A
3/31/20141,117194N/A144N/A
12/31/20131,090188N/A111N/A

애널리스트 미래 성장 예측

수입 대 저축률: 002317 의 연간 예상 수익 증가율( 41.7% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: 002317 의 연간 수익( 41.7% ) CN 시장( 26.2% 보다 빠르게 성장할 것으로 예상됩니다. 26.2% 연간).

고성장 수익: 002317 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: 002317 의 수익(연간 16.3% ) CN 시장( 13.9% 보다 빠르게 성장할 것으로 예상됩니다. 13.9% 연간).

고성장 수익: 002317 의 수익(연간 16.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 002317 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 8.7 %).

성장 기업 발견

7D

1Y

7D

1Y

7D

1Y